Chronic leukemia

Chronic leukemia

nclex

nclex

NCLEX Q&A with Jannah Amiel
Extrinsic hemolytic normocytic anemia: Pathology review
Heart blocks: Pathology review
Malabsorption syndromes: Pathology review
Dyslipidemias: Pathology review
Pituitary tumors: Pathology review
Pericardial disease: Pathology review
Multiple endocrine neoplasia: Pathology review
Peripheral artery disease: Pathology review
Theoretical Foundations of Nursing
Study for Success: Habits Every Nursing Student Should Adopt
Major depressive disorder
Bipolar and related disorders
Suicide
Schizophrenia
Delirium
Cluster C personality disorders
Cluster B personality disorders
Cannabis use disorder
Cocaine use disorder
Narcolepsy (NORD)
Mood disorders: Pathology review
Personality disorders: Pathology review
Drug misuse, intoxication and withdrawal: Hallucinogens: Pathology review
Eating disorders: Pathology review
Psychiatric emergencies: Pathology review
Amnesia, dissociative disorders and delirium: Pathology review
Serotonin and norepinephrine reuptake inhibitors
Atypical antipsychotics
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Fat-soluble vitamin deficiency and toxicity: Pathology review
Huntington disease
Cri du chat syndrome
Marfan syndrome
Sickle cell disease (NORD)
Myocardial infarction
Peripheral artery disease
Hypertension
Tetralogy of Fallot
Heart failure
Myocarditis
Atherosclerosis and arteriosclerosis: Pathology review
Shock: Pathology review
Diabetes mellitus
Diabetic nephropathy
Diabetes insipidus and SIADH: Pathology review
Sleep apnea
Celiac disease
Crohn disease
Ulcerative colitis
Bowel obstruction
Jaundice
Neonatal hepatitis
Iron deficiency anemia
Chronic leukemia
Coagulation disorders: Pathology review
Anaphylaxis
Asthma
Candida
Osteomyelitis
Osteoarthritis
Scleroderma
Epidural hematoma
Shaken baby syndrome
Seizures and epilepsy
Frontotemporal dementia
Multiple sclerosis
Guillain-Barre syndrome
Seizures: Pathology review
Hypermagnesemia
Hypercalcemia
Hyponatremia
Chronic kidney disease
Electrolyte disturbances: Pathology review
Benign prostatic hyperplasia
Placenta previa
Placental abruption
Gestational diabetes
Gestational hypertension
Postpartum hemorrhage
Miscarriage
Sudden infant death syndrome
Acute respiratory distress syndrome
Pulmonary embolism
Pharmacokinetics: Drug elimination and clearance
Drug administration and dosing regimens
Cholinomimetics: Direct agonists
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Beta blockers
ACE inhibitors, ARBs and direct renin inhibitors
Class III antiarrhythmics: Potassium channel blockers
Lipid-lowering medications: Statins
Insulins
Anticoagulants: Heparin
Anticoagulants: Warfarin
Glucocorticoids
Sympathomimetics: Direct agonists
Neuromuscular blockers
Uterine stimulants and relaxants
Medication overdoses and toxicities: Pathology review
Normal heart sounds
Oxytocin and prolactin
Thyroid hormones
Insulin
Synthesis of adrenocortical hormones
Phosphate, calcium and magnesium homeostasis
Erythropoietin
Respiratory acidosis
Metabolic acidosis
Pregnancy
Breastfeeding
Pulmonary shunts
Renin-angiotensin-aldosterone system
Calcium channel blockers
Thiazide and thiazide-like diuretics
Positive inotropic medications
Lipid-lowering medications: Fibrates
Antidiuretic hormone
Hypoglycemics: Insulin secretagogues
Acid reducing medications
Pyloric stenosis
Graft-versus-host disease
Myasthenia gravis
Autoimmune hemolytic anemia
Food allergy
Vaccinations
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Febrile seizure
Brain herniation
Muscarinic antagonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Nonbenzodiazepine anticonvulsants
Opioid antagonists
Acid-base map and compensatory mechanisms
Metabolic alkalosis
Ventilation-perfusion ratios and V/Q mismatch
Emphysema
Respiratory alkalosis
Diabetes insipidus
Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Pharmacokinetics: Drug absorption and distribution
Adrenergic antagonists: Presynaptic
Selective serotonin reuptake inhibitors
Atypical antidepressants
Cell wall synthesis inhibitors: Penicillins
Hepatitis medications
Migraine medications
Osmotic diuretics
Androgens and antiandrogens
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Puberty and Tanner staging
Carbon dioxide transport in blood

Transcript

Watch video only

With chronic leukemia, “leuk” refers to white blood cells, and “emia” refers to the blood; so in chronic leukemia there are lots of partially developed white blood cells in the blood over a long period of time.

These partially developed white blood cells interfere with the development and function of healthy white blood cells, platelets, and red blood cells.

Now, every blood cell starts its life in the bone marrow as a hematopoietic stem cell.

Hematopoietic stem cells are multipotent -- meaning that they can give rise to both myeloid or lymphoid blood cells.

If a hematopoietic stem cell develops into a myeloid cell, it’ll mature into an erythrocyte -- or a red blood cell, a thrombocyte -- or a platelet, or a leukocyte -- or a white blood cell, like a monocyte or granulocyte.

Granulocytes are cells with tiny granules inside of them -- they include neutrophils, basophils, and eosinophils.

If a hematopoietic stem cell develops into a lymphoid cell, on the other hand, it’ll mature into some other kind of leukocyte: a T cell, a B cell, or a natural killer cell, which are referred to as lymphocytes.

Once the various blood cells form, they leave the bone marrow, and travel around the blood, or settle down in tissues and organs like the lymph nodes and spleen.

Chromosomal abnormality in hematopoietic stem cells that are destined to become leukocytes is the most common cause of chronic leukemia.

Some examples of abnormalities include a chromosomal deletion, where part of a chromosome is missing, a trisomy, where there’s one extra chromosome, and a translocation, where two chromosomes break and swap parts with one another.

Now there are two types of chronic leukemia.

The first is chronic myeloid leukemia, CML, which is caused by a particular chromosomal translocation that affects granulocytes.

The second is chronic lymphocytic leukemia, CLL, which is caused by a variety of chromosomal mutations that affect lymphocytes, in particular B cells.

Both CML and CLL cause cells to mature only partially, and that’s a key distinction from acute leukemias where the cells don’t mature at all.

As a result, these abnormal, premature leukocytes don’t work effectively, which weakens the immune system.

In addition, the chromosomal changes alters the cell’s normal cell cycle.

As a result, in CML the cells start to divide way too quickly and in CLL the cell’s don’t die when they should -- and in both situations, we’re left with way too many of these premature cells.

So over time, premature leukocytes accumulate in the bone marrow, until eventually they spill out into the blood.

Now some of these guys settle down in organs and tissues across the body, but others keep circulating in the blood.

With a bunch of extra cells in the blood, all the healthy cells get “crowded out”, and it’s tough for them to survive with the extra competition for nutrients.

This causes cytopenias, or a reduction in the number of healthy blood cells, like anemia, which is a reduction of healthy red blood cells, thrombocytopenia, a reduction of healthy platelets, and leukopenia, or a reduction of healthy leukocytes.

In chronic myeloid leukemia, the most common cause is a chromosome translocation which results in a Philadelphia chromosome.

And that’s where a portion of chromosome 9’s long arm switches with a portion of chromosome 22’s long arm -- and we write that as t(9;22) -- t because it’s a translocation, and 9 and 22 because those are the chromosomes that switch genetic information.

This results in a modified chromosome 9 and modified chromosome 22, and it’s the chromosome 22 that’s called the Philadelphia chromosome.

So, in the Philadelphia chromosome, a chromosome 22 gene, which is the BCR gene, ends up sitting right next to a chromosome 9 gene, the ABL gene.

When they’re combined it forms a fusion gene called BCR ABL, which codes for a protein also called BCR ABL, which is a constitutively active tyrosine kinase, meaning that BCR ABL is like an “on/off” switch stuck in the “on” position.

Since BCR ABL helps control various cellular functions like cell division, having it always “on” forces myeloid cells to keep dividing quicker than they should, which causes a buildup of the premature leukocytes in the bone marrow, that eventually spill into the blood.

The premature leukocytes then move to the liver and spleen, causing swelling of those organs or “hepatosplenomegaly”.

And because these CML cells divide quicker than they should, there’s a high chance that further genetic mutations can happen!

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  3. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  4. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  5. "Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future" Cells (2021)
  6. "Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future" Cells (2021)
  7. "Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies" Journal of Clinical and Experimental Hematopathology (2020)
  8. "Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management" American Journal of Hematology (2019)